Lipids for psychiatrists - An overview

Journal of Psychopharmacology

Volumn 19, Issue 6 SUPPL., 2005, Pages 66-75

  Young, Ian S ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Cholesterol; HDL; LDL; Lipid lowering drugs; Lipid metabolism; Statins; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; RESIN; TRIACYLGLYCEROL;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG TARGETING; DYSLIPIDEMIA; FLUSHING; HUMAN; LIFESTYLE; LIPID METABOLISM; LIVER DYSFUNCTION; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHIATRIST; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; LIPIDS; PSYCHIATRY; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33750003868     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881105058374     Document Type: Review

References (112)

1. Akinboboye O, Idris O, Akinboboye O, Akinkugbe O (2003) Trends in coronary artery disease and associated risk factors in sub-Saharan Africans. J Hum Hypertens 17: 381-387
2. Ann Intern Med. 90: 85-91
3. Ansell B J, Navab M, Watson K E, Fonarow G C, Fogelman A M (2004) Anti-inflammatory properties of HDL. Rev Endocr Metab Disord. J: 351-358
4. Ascaso J F, Fernandez-Cruz A, Gonzalez Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pia G, Pintó X, Plaza I, Rubiés-Prat J (2004). Significance of high density lipoprotein- cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. Am J Cardiovasc Drugs. 4: 299-314
5. Assmann G, Schulte H. (1987) The Prospective Cardiovascular Munster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol. 59: 9G-17G
6. Assmann G, Cullen P, Schulte H (1998) The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 19 Suppl A: A2-11
7. Assmann G, Schulte H, von Eckardstein A, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl: S11-20
8. Austin M A (1997) Triacylglycerol and coronary heart disease. Proc Nutr Soc. 56: 667-670
9. Austin M A, Hokanson J E, Edwards K L (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81: 7B-12B
10. Austin M A, Hutter C M, Zimmern R L, Humphries SE. (2004) Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 160: 421-429
11. Austin M A, McKnight B, Edwards K L, Bradley C M, McNeely M J, Psaty B M, Brunzell J D, Motulsky A G (2000) Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation. 101: 2777-2782
12. Bairaktari E T, Seferiadis K I, Elisaf M S (2005) Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther 10: 45-54
13. Barrans A, Jaspard B, Barbaras R, Chap H, Perret B, Collet X (1996) Pre-beta HDL: structure and metabolism. Biochim Biophys Acta 1300: 73-85
14. Barter P (2005) The inflammation: lipoprotein cycle. Aheroscler Suppl 6: 15-20
15. Brohet C, Banai S, Alings A M, Massaad R, Davies M J, Allen C (2005) LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 21: 571-578
16. Bucher H C, Griffith L E, Guyatt G H (1999) Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 19: 187-195
17. Carstensen M, Thomsen C, Hermansen K (2003) Incremental area under response curve more accurately describes the triglyceride response to an oral fat load in both healthy and type 2 diabetic subjects. Metabolism. 52: 1034-1037
18. Chapman M J, Assmann G, Fruchart J C, Shepherd J, Sirtori C; European Consensus Panel on HDL-C (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20: 1253-1268
19. Clark A B, Holt J M (1997) Identifying and managing patients with hyperlipidemia. Am J Manag Care 3: 1211-1219
20. Cooper G R, Smith S J, Myers G L, Sampson E J, Magid E (1994) Estimating and minimizing effects of biologic sources of variation by relative range when measuring the mean of serum lipids and lipoproteins. Clin Chem 40: 227-232
21. Cromwell W C, Otvos J D (2004) Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6: 381-387
22. Cuzzocrea S, Dugo L, Patel N S, Di Paola R, Cockerill G W, Genovese T, Thiemermann C (2004) High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock 21: 342-351
23. De Angelis G (2004) The influence of statin characteristics on their safety and tolerability. Int J Clin Pract 58: 945-955
24. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Gifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk U, Pyorala K, Rodicio J L, Sans S, Sansory V, Sechtem U, Silber S, Thomsene T, Wood D (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601-1610
25. de Grooth G J, Klerkx A H, Stroes E S, Stalenhoef A F, Kastelein J J, Kuivenhoven J A (2004) A review of CETP and its relation to atherosclerosis. J Lipid Res 45: 1967-1974
26. de Lorgeril M, Salen P, Martin J L, Monjaud I, Delaye J, Mamelle N (1999) Mediterranean diet, traditional risk factors, and the rate of car-diovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99: 779-785
27. Devroey D, Velkeniers B, Duquet W, Betz W (2003) Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta Cardiol 58: 179-184
28. Edwards J E, Moore R A (2003) Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 4: 18
29. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2001) 285: 2486-2497
30. Feussner G, Piesch S, Dobmeyer J, Fischer C. (1997) Genetics of type III hyperlipoproteinemia. Genet Epidemiol 14: 283-297
31. Fidge N H (1999) High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 40: 187-201
32. Fielding C J, Fielding P E (2001) Cellular cholesterol efflux. Biochim Biophys Acta 1533: 175-89
33. Fisher R M, Miles J M, Kottke B A, Frayn K N, Coppack S W (1997) Very-low-density lipoprotein subfraction composition and metabolism by adipose tissue. Metabolism 46: 605-610
34. Folsom A R, Kuba K, Leupker R V, Jacobs D R, Frantz ID Jr (1983) Lipid concentrations in serum and EDTA-treated plasma from fasting and nonfasting normal persons, with particular regard to high-density lipoprotein cholesterol. Clin Chem 29: 505-508
35. Fredenrich A, Bayer P (2003) Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab 29: 201-205
36. Frick M H, Elo O, Haapa K, Heinonen O P, Heinsalmi P, Helo P, Huttunen J K, Kaitaniemi P, Koskinen P, Manninen V, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245
37. Friedwald W T, Levy R I, Fredrickson D S (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18: 499
38. Galeano N F, Al-Haideri M, Keyserman F, Rumsey S C, Deckelbaum R J (1998) Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39: 1263-1273
39. Gibbons G F, Wiggins D, Brown A M, Hebbachi A M (2004) Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 32: 59-64
40. Goldberg R J, Burchfiel C M, Benfante R, Chiu D, Reed D M, Yano K (1995) Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-year findings from the Honolulu Heart Program. Arch Intern Med 155: 686-694
41. Graham D J, Staffa J A, Shatin D, Andrade S E, Schech S D, La Grenade L, Gurwitz J H, Chan K A, Goodman M J, Platt R. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590
42. Griffin B A (1999) Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc 58: 163-169
43. Griffin B A, Caslake M J, Yip B, Tait G W, Packard C J, Shepherd J (1990) Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83: 59-67
44. Guo Q, Kohen Avramoglu R, Adeli K (2005) Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48- containing lipoprotein particles in the fasting state: Evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 54: 689-697
45. Hamsten A, Silveira A, Boquist S, Tang R, Bond M G, de Faire U, Bjorkegren J (2005) The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J Am Coll Cardiol 45: 1013-1017
46. Hansson G K (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695
47. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
48. Hokanson J E, Austin M A (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3: 213-219
49. Hughes T A, Elam M B, Applegate W B, Bond M G, Hughes S M, Wang X, Tolley E A, Bittle J B, Stentz F B, Kang E S (1995) Postprandial lipoprotein responses in hypertriglyceridemic subjects with and without cardiovascular disease. Metabolism 44: 1082-1098
50. Iribarren C, Reed D M, Chen R, Yano K, Dwyer J H (1995) Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation 92: 2396-2403
51. Jansen A C, van Aalst-Cohen E S, Tanck M W, Cheng S, Fontecha M R, Li J, Defesche J C, Kastelein J J (2005) Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 5 May; [Epub ahead of print]
52. Jones P H, Davidson M H (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95: 120-122
53. Julius U (2003) Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 111: 246-250
54. Kafonek S D, Donovan L, Lovejoy K L, Bachorik P S (1996) Biological variation of lipids and lipoproteins in fingerstick blood. Clin Chem 42: 2002-2007
55. Kannel W B, Castelli W P, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90: 85-91
56. Katan M B (2004) The rise and fall of postprandial lipids. Neth J Med 62: 265-266
57. Kelley G A, Kelley K S, Vu Tran Z (2005) Aerobic exercise, lipids and lipoproteins in overweight and obese adults: a meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 12 Apr; [Epub ahead of print]
58. Kosoglou T, Statkevich P, Johnson-Levonas A O, Paolini J F, Bergman A J, Alton K B (2005) Ezetimibe : a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44: 467-494
59. Kromhout D (2001) Epidemiology of cardiovascular diseases in Europe. Public Health Nutr 4 (2B): 441-457
60. Kwiterovich P O Jr (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86: 5L-10L
61. Lamarche B, Lemieux I, Despres J P (1999) The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25: 199-211
62. Lamarche B, St-Pierre A C, Ruel I L, Cantin B, Dagenais G R, Despres J P (2001) A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17: 859-865
63. Lampe F C, Morris R W, Walker M, Shaper A G, Whincup PH (2005) Trends in rates of different forms of diagnosed coronary heart disease, 1978 to 2000: prospective, population based study of British men BMJ 330: 1046
64. LaRosa J C, Grundy S M, Waters D D, Shear C, Barter P, Fruchart J C, Gotto A M, Greten H, Kastelein J J, Shepherd J, Wenger NK Treating to New Targets (TNT) Investigators. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435
65. Lee J Y, Parks J S (2005) ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 16: 19-25
66. Leren T P (2004) Cascade genetic screening for familial hypercholesterolemia. Clin Genet 66: 483-487
67. Li J M, Mukamal K J (2004) An update on alcohol and atherosclerosis. Curr Opin Lipidol 15: 673-680
68. Libby P (2001) Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am J Cardiol 88 (12A): 3N-8N
69. Lindsey C C, Graham M R, Johnston T P, Kiroff C G, Freshley A (2004) A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level. Pharmacotherapy 24: 167-172
70. McKenney J M (2004) Optimizing LDL-C lowering with statins. Am J Ther 11: 54-59
71. Maeda K, Noguchi Y, Fukui T (2003) The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 37: 283-290
72. Malloy M J, Kane J P (2001) A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 47: 111-136
73. Mangion D M, Roy S S (1993) Serum lipids and coronary heart disease in British elderly. Postgrad Med J 69: 609-614
74. Maruyama C, Imamura K, Teramoto T (2003) Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 10: 186-191
75. Morgan J, Carey C, Lincoff A, Capuzzi D (2004) High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 6: 359-365
76. Nicholls S, Lundman P (2004) The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Semin Vasc Med 4: 187-195
77. Nielsen L B (1996) Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 123: 1-15
78. Packard C, Caslake M, Shepherd J (2000a) The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74: S17-22
79. Packard C J, Demant T, Stewart J P, Bedford D, Caslake M J, Schwertfeger G, Bedynek A, Shepherd J, Seidel D (2000b) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41: 305-318
80. Pearson T A, Denke M A, McBride P E, Battisti W P, Brady W E, Palmisano J (2005) A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 80: 587-595
81. Pedersen T R, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson A G, Wedel H; Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl 5: 81-87
82. Pfeffer M A, Keech A, Sacks F M, Cobbe S M, Tonkin A, Byington R P, Davis B R, Friedman C P, Braunwald E. (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105: 2341-2346
83. Pirich C, Mullner M, Sinzinger H (2000) Prevalence and relevance of thyroid dysfunction in 1922 cholesterol screening participants. Clin Epidemiol 53: 623-629
84. Poobalan A, Aucott L, Smith W C, Avenell A, Jung R, Broom J, Grant A M (2004) Effects of weight loss in overweight/obese individuals and long-term lipid outcomes - a systematic review. Obes Rev 5: 43-50
85. Reed D M, Strong J P, Resch J, Hayashi T (1989) Serum lipids and lipoproteins as predictors of atherosclerosis. An autopsy study. Arteriosclerosis 9: 560-564
86. Reynolds T M, Twomey P, Wierzbicki A S (2002) Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 9: 183-190
87. Reynolds T M, Twomey P J, Wierzbicki A S (2004) Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Curr Med Res Opin 20: 811-818
88. Robins S J, Collins D, Wittes J T, Papademetriou V, Deedwania P C, Schaefer E J, McNamara J R, Kashyap M L, Hershman J M, Wexler L F, Rubins HB; VA-HIT Study Group (2001) Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585-1591
89. Schenck-Gustafsson K (1996) Risk factors for cardiovascular disease in women: assessment and management. Eur Heart J 17 (Suppl D): 2-8
90. Segrest J P (2002) The role of non-LDL:non-HDL particles in atherosclerosis. Curr Diab Rep 2: 282-288
91. Sever P S, Poulter N R, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen S E, Kristinsson A, McInnes G T, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28: 1151-1157
92. Sniderman A D (2004) Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol 94: 30F-34F
93. Soma M R, Corsini A, Paoletti R. (1992) Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 64-65 Spec No: 1-15
94. Stamler J, Shekelle R. (1988) Dietary cholesterol and human coronary heart disease. The epidemiologic evidence. Arch Pathol Lab Med 112: 1032-1040
95. Steiner G. (2004) Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am 33: 545-555
96. Stemmermann G N, Chyou P H, Kagan A, Nomura A M, Yano K (1991) Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program. Arch Intern Med 151: 969-972
97. Stumvoll M, Goldstein B J, van Haeften T W (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346
98. Tang J L, Armitage J M, Lancaster T, Silagy C A, Fowler G H, Neil H A (1998) Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316: 1213-1220
99. Thompson G R (1990) Primary hyperlipidaemia. Br Med Bull 46: 986-1004
100. Thulaseedharan N, Augusti K T (1995) Risk factors for coronary heart disease in noninsulin dependent diabetes mellitus (NIDDM). Indian Heart J 47: 471-476
101. Toth P P (2004) Low-density lipoprotein reduction in high-risk patients: how low do you go? Curr Atheroscler Rep 6: 348-352
102. Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke M C, Peeters P H, van der Schouw Y T, Boeing H, Hoffman K, Boffetta P, Nagel G, Masala G, Krogh V, Panico S, Tumino R, Vineis P, Bamia C, Naska A, Benetou V, Ferrari P, Slimani N, Pera G, Martinez-Garcia C, Navarro C, Rodriguez-Barranco M, Dorronsoro M, Spencer E A, Key T J, Bingham S, Khaw K T, Kesse E, Clavel-Chapelon F, Boutron-Ruault M C, Berglund G, Wirfalt E, Hallmans G, Johansson I, Tjonneland A, Olsen A, Overvad K, Hundborg H H, Riboli E, Trichopoulos D (2005) Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ 330: 991
103. Twickler M, Cramer M J, Erkelens W (2003) Expression of an atherogenic dyslipidemic phenotype in the postprandial period. Am J Cardiol 91: 258
104. Twickler T B, Dallinga-Thie G M, Cohn J S, Chapman M J (2004) Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 109: 1918-1925
105. UK HDL-C Consensus Group (2004) Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin 20: 241-247
106. von Eckardstein A, Hersberger M, Rohrer L (2005) Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 8: 147-152
107. Wang T W (2004) Managing hyperlipidaemia. Practitioner 248: 660-668
108. Wilder L B, Bachorik P S, Finney C A, Moy T F, Becker D M (1995) The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med 99: 374-377
109. Williams B, Poulter N R, Brown M J, Davis M, McInnes G T, Potter J F, Sever P S, Thom SM; BHS guidelines working party, for the British Hypertension Society. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 328: 634-640
110. Wilson P W, Evans J C (1993) Coronary artery disease prediction. Am J Hypertens 6: 309S-313S
111. Yaari S, Goldbourt, Even-Zohar S, Neufeld H N (1981) Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10000 men. Lancet I (8228): 1011-1015
112. Yildirimkaya M, Bil Gi C, Ozata M, Nazaroglu N K, Gundogan M A, Kutluay T, Karaca L. (1996) Biological variation of serum lipids and lipoproteins in patients with clinically well controlled non insulin dependent diabetes mellitus. Endocr J 43: 345-351